Uveal melanoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}}{{AE}}{{Fs}}, {{Simrat}} | {{CMG}}{{AE}}{{Fs}}, {{Simrat}} | ||
==Overview== | ==Overview== | ||
Pharmacologic medical therapy is recommended among [[Patient|patients]] with [[Metastasis|metastatic]] [[disease]] and include [[chemotherapy]], [[immunotherapy]], and [[targeted therapy]]. | |||
==Medical Therapy== | ==Medical Therapy== | ||
Pharmacologic medical therapy is recommended among patients with metastatic disease: | Pharmacologic medical [[therapy]] is recommended among [[Patient|patients]] with [[Metastasis|metastatic]] disease: | ||
* Chemotherapy | *[[Chemotherapy]] | ||
** Dacarbazine | **[[Dacarbazine]] | ||
** Temozolomide | **[[Temozolomide]] | ||
** Cisplatin | **[[Cisplatin]] | ||
** Treosulfan | **[[Treosulfan]] | ||
** Fotemustine | **[[Fotemustine]] | ||
* Immunotherapy | *[[Immunotherapy]] | ||
** Checkpoint blockade | ** Checkpoint blockade | ||
*** Pembrolizumab | ***[[Pembrolizumab]] | ||
*** Ipilimumab + nivolumab | ***[[Ipilimumab]] + [[nivolumab]] | ||
*** Ipilimumab + nivolumab | ***[[Ipilimumab]] + [[nivolumab]] | ||
*** Ipilimumab + radioembolization | ***[[Ipilimumab]] + radioembolization | ||
*** Ipilimumab + nivolumab +radioembolization | ***[[Ipilimumab]] + [[nivolumab]] +radioembolization | ||
** TILs (tumor-infiltrating lymphocytes) | ** TILs (tumor-infiltrating lymphocytes) | ||
** T cell redirection | **[[T cell]] redirection | ||
** | **[[Antibody]]–[[drug]] conjugate | ||
*** Glembatumumab vedotin | *** Glembatumumab vedotin | ||
* Targeted therapy | *[[Targeted therapy]] | ||
** PKC (protein kinase | **[[Protein kinase C|PKC]] ([[protein kinase C]])/ MEK | ||
*** AEB071 + BYL719 | *** AEB071 + BYL719 | ||
*** Intermittent selumetinib | *** Intermittent selumetinib | ||
*** Selumetinib +/– paclitaxel | *** Selumetinib +/– [[paclitaxel]] | ||
*** Binimetinib + AEB071 | ***[[Binimetinib]] + AEB071 | ||
** | ** Multi-kinase inhibition | ||
*** Sorafenib (STREAM) | ***[[Sorafenib]] (STREAM) | ||
*** Cabozantinib versus temozolomide/ dacarbazine | ***[[Cabozantinib]] versus [[temozolomide]]/ [[dacarbazine]] | ||
** Epigenetic therapy | ** Epigenetic therapy | ||
*** HDAC (histone deacetylase) inhibition | ***[[Histone deacetylase 2|HDAC]] ([[histone deacetylase]]) inhibition | ||
**** Vorinostat | ****[[Vorinostat]] | ||
**** Pembrolizumab + entinostat (PEMDAC) | ****[[Pembrolizumab]] + entinostat (PEMDAC) | ||
*** BET (bromodomain and extra-terminal motif) inhibition | *** BET (bromodomain and extra-terminal motif) inhibition | ||
** Liver-directed therapy | ** Liver-directed therapy | ||
*** IHP (isolated hepatic perfusion) | *** IHP (isolated [[hepatic]] perfusion) | ||
*** PHP ( <br /> | *** PHP ( <br /> | ||
Revision as of 03:22, 16 August 2019
Uveal melanoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Uveal melanoma medical therapy On the Web |
American Roentgen Ray Society Images of Uveal melanoma medical therapy |
Risk calculators and risk factors for Uveal melanoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D., Simrat Sarai, M.D. [2]
Overview
Pharmacologic medical therapy is recommended among patients with metastatic disease and include chemotherapy, immunotherapy, and targeted therapy.
Medical Therapy
Pharmacologic medical therapy is recommended among patients with metastatic disease:
- Chemotherapy
- Immunotherapy
- Checkpoint blockade
- Pembrolizumab
- Ipilimumab + nivolumab
- Ipilimumab + nivolumab
- Ipilimumab + radioembolization
- Ipilimumab + nivolumab +radioembolization
- TILs (tumor-infiltrating lymphocytes)
- T cell redirection
- Antibody–drug conjugate
- Glembatumumab vedotin
- Checkpoint blockade
- Targeted therapy
- PKC (protein kinase C)/ MEK
- AEB071 + BYL719
- Intermittent selumetinib
- Selumetinib +/– paclitaxel
- Binimetinib + AEB071
- Multi-kinase inhibition
- Sorafenib (STREAM)
- Cabozantinib versus temozolomide/ dacarbazine
- Epigenetic therapy
- HDAC (histone deacetylase) inhibition
- Vorinostat
- Pembrolizumab + entinostat (PEMDAC)
- BET (bromodomain and extra-terminal motif) inhibition
- HDAC (histone deacetylase) inhibition
- Liver-directed therapy
- IHP (isolated hepatic perfusion)
- PHP (
- PKC (protein kinase C)/ MEK